Investment Plan: EIB signs collaboration with Israel Innovation Authority and €50 million financing agreement with Pluristem to develop therapies for COVID-19 and other unmet medical needs
date: 07/05/2020
The EIB will also back Pluristem with €50 million in financing, which will help the company to advance the clinical development of its cell therapies and address a number of severe medical conditions, including COVID-19. The deal is the first Israeli-European project guaranteed by the European Fund for Strategic Investments, the financial pillar of the Investment Plan for Europe, a joint initiative of the EIB and the European Commission.